AP31969 / Acesion - LARVOL DELTA

Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation (PharmaTimes) - "The company said the first participants have now entered the randomised, double‑blind, placebo‑controlled study, which will recruit 200 patients across eight European countries and is expected to complete in the first quarter of 2027....The trial’s primary efficacy endpoint is atrial fibrillation burden, defined as the percentage of time a participant spends in atrial fibrillation."

Trial completion date • Trial status • Atrial Fibrillation

END-AF-1: Clinical Randomised Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Acesion Pharma

New P2 trial • Atrial Fibrillation • Cardiovascular

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: Acesion Pharma | Recruiting ➔ Completed

Trial completion

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study with AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Trial completion date: May 2024 ➔ Sep 2024 | Trial primary completion date: May 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Not yet recruiting ➔ Recruiting

Enrollment open

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Not yet recruiting | Sponsor: Acesion Pharma

New P1 trial